These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12570021)

  • 1. Binding of KRH-594, an antagonist of the angiotensin II type 1 receptor, to cloned human and rat angiotensin II receptors.
    Inada Y; Nakane T; Chiba S
    Fundam Clin Pharmacol; 2002 Aug; 16(4):317-23. PubMed ID: 12570021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic profiles of KRH-594, a novel nonpeptide angiotensin II-receptor antagonist.
    Tamura K; Okuhira M; Amano H; Inokuma K; Hirata T; Mikoshiba I; Hashimoto K
    J Cardiovasc Pharmacol; 1997 Nov; 30(5):607-15. PubMed ID: 9388043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of KR-30988, a novel non-peptide AT1 receptor antagonist, in rat, rabbit and dog.
    Lee BH; Lee SH; Jung YS; Seo HW; Yoo SE; Shin HS
    J Pharm Pharmacol; 1999 Oct; 51(10):1191-200. PubMed ID: 10579691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpeptide AT1-receptor antagonist.
    Lee SH; Jung YS; Lee BH; Yun SI; Yoo SE; Shin HS
    J Cardiovasc Pharmacol; 1999 Mar; 33(3):367-74. PubMed ID: 10069670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist.
    Robertson MJ; Barnes JC; Drew GM; Clark KL; Marshall FH; Michel A; Middlemiss D; Ross BC; Scopes D; Dowle MD
    Br J Pharmacol; 1992 Dec; 107(4):1173-80. PubMed ID: 1467838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174.
    Dickinson KE; Cohen RB; Skwish S; Delaney CL; Serafino RP; Poss MA; Gu Z; Ryono DE; Moreland S; Powell JR
    Br J Pharmacol; 1994 Sep; 113(1):179-89. PubMed ID: 7812609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro pharmacological properties of KRH-594, a novel angiotensin II type 1 receptor antagonist.
    Tamura K; Okuhira M; Mikoshiba I; Hashimoto K
    Biol Pharm Bull; 1997 Aug; 20(8):850-5. PubMed ID: 9300129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.
    Vanderheyden PM; Fierens FL; De Backer JP; Fraeyman N; Vauquelin G
    Br J Pharmacol; 1999 Feb; 126(4):1057-65. PubMed ID: 10193788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan.
    Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
    Am J Hypertens; 2000 Sep; 13(9):1005-13. PubMed ID: 10981551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II type 1 receptor blockade prevents up-regulation of angiotensin II type 1A receptors in rat injured artery.
    Tazawa S; Nakane T; Chiba S
    J Pharmacol Exp Ther; 1999 Feb; 288(2):898-904. PubMed ID: 9918604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in vitro pharmacological profile of KR31080, a nonpeptide AT1 receptor antagonist.
    Hong KW; Kim CD; Lee SH; Yoo SE
    Fundam Clin Pharmacol; 1998; 12(1):64-9. PubMed ID: 9523186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding.
    Fierens FL; Vanderheyden PM; De Backer JP; Vauquelin G
    Eur J Pharmacol; 1999 May; 372(2):199-206. PubMed ID: 10395100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding and signal transduction of the cloned vascular angiotensin II (AT1a) receptor cDNA stably expressed in Chinese hamster ovary cells.
    Webb ML; Monshizadegan H; Dickinson KE; Serafino R; Moreland S; Michel I; Seiler SM; Murphy TJ
    Regul Pept; 1993 Mar; 44(2):131-9. PubMed ID: 8469768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the insurmountable angiotensin AT1 receptor antagonist candesartan and the surmountable antagonist losartan on ischemia/reperfusion injury in rat hearts.
    Wang QD; Sjöquist PO
    Eur J Pharmacol; 1999 Sep; 380(1):13-21. PubMed ID: 10513555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for AT2 receptors.
    Chang RS; Lotti VJ; Chen TB; O'Malley SS; Bendesky RJ; Kling PJ; Kivlighn SD; Siegl PK; Ondeyka D; Greenlee WJ
    Eur J Pharmacol; 1995 Dec; 294(2-3):429-37. PubMed ID: 8750703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors.
    Vanderheyden PM; Fierens FL; De Backer J; Vauquelin G
    Biochem Pharmacol; 2000 Apr; 59(8):927-35. PubMed ID: 10692557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist.
    Noda M; Shibouta Y; Inada Y; Ojima M; Wada T; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
    Biochem Pharmacol; 1993 Jul; 46(2):311-8. PubMed ID: 8347154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of renal angiotensin II receptors using subtype selective antagonists.
    Edwards RM; Stack EJ; Weidley EF; Aiyar N; Keenan RM; Hill DT; Weinstock J
    J Pharmacol Exp Ther; 1992 Mar; 260(3):933-8. PubMed ID: 1545405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II binding sites in the rat fetus: characterization of receptor subtypes and interaction with guanyl nucleotides.
    Feuillan PP; Millan MA; Aguilera G
    Regul Pept; 1993 Mar; 44(2):159-69. PubMed ID: 8469771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors.
    Verheijen I; Fierens FL; Debacker JP; Vauquelin G; Vanderheyden PM
    Fundam Clin Pharmacol; 2000; 14(6):577-85. PubMed ID: 11206708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.